Literature DB >> 20810612

Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis.

Toshitake Hyodo1, Takashi Oda, Yuichi Kikuchi, Keishi Higashi, Taketoshi Kushiyama, Kojiro Yamamoto, Muneharu Yamada, Shigenobu Suzuki, Ryota Hokari, Manabu Kinoshita, Shuhji Seki, Hidehiko Fujinaka, Tadashi Yamamoto, Soichiro Miura, Hiroo Kumagai.   

Abstract

The voltage-gated potassium channel Kv1.3 has been recently identified as a molecular target that allows the selective pharmacological suppression of effector memory T cells (T(EM)) without affecting the function of naïve T cells (T(N)) and central memory T cells (T(CM)). We found that Kv1.3 was expressed on glomeruli and some tubules in rats with anti-glomerular basement membrane glomerulonephritis (anti-GBM GN). A flow cytometry analysis using kidney cells revealed that most of the CD4(+) T cells and some of the CD8(+) T cells had the T(EM) phenotype (CD45RC(-)CD62L(-)). Double immunofluorescence staining using mononuclear cell suspensions isolated from anti-GBM GN kidney showed that Kv1.3 was expressed on T cells and some macrophages. We therefore investigated whether the Kv1.3 blocker Psora-4 can be used to treat anti-GBM GN. Rats that had been given an injection of rabbit anti-rat GBM antibody were also injected with Psora-4 or the vehicle intraperitoneally. Rats given Psora-4 showed less proteinuria and fewer crescentic glomeruli than rats given the vehicle. These results suggest that T(EM) and some macrophages expressing Kv1.3 channels play a critical role in the pathogenesis of crescentic GN and that Psora-4 will be useful for the treatment of rapidly progressive glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20810612      PMCID: PMC3006300          DOI: 10.1152/ajprenal.00374.2010

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  62 in total

1.  Molecular cloning of a glibenclamide-sensitive, voltage-gated potassium channel expressed in rabbit kidney.

Authors:  X Yao; A Y Chang; E L Boulpaep; A S Segal; G V Desir
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

Review 2.  Modulators of crescentic glomerulonephritis.

Authors:  R C Atkins; D J Nikolic-Paterson; Q Song; H Y Lan
Journal:  J Am Soc Nephrol       Date:  1996-11       Impact factor: 10.121

3.  Crucial role of CD8-positive lymphocytes in glomerular expression of ICAM-1 and cytokines in crescentic glomerulonephritis of WKY rats.

Authors:  H Fujinaka; T Yamamoto; L Feng; K Kawasaki; E Yaoita; S Hirose; S Goto; C B Wilson; M Uchiyama; I Kihara
Journal:  J Immunol       Date:  1997-05-15       Impact factor: 5.422

4.  Modulation of antibody-mediated glomerular injury in vivo by bacterial lipopolysaccharide, tumor necrosis factor, and IL-1.

Authors:  N I Tomosugi; S J Cashman; H Hay; C D Pusey; D J Evans; A Shaw; A J Rees
Journal:  J Immunol       Date:  1989-05-01       Impact factor: 5.422

5.  SnapShot: effector and memory T cell differentiation.

Authors:  Matthew E Pipkin; Anjana Rao
Journal:  Cell       Date:  2009-08-07       Impact factor: 41.582

6.  Urinary CD4+ effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Wayel H Abdulahad; Cees G M Kallenberg; Pieter C Limburg; Coen A Stegeman
Journal:  Arthritis Rheum       Date:  2009-09

7.  Abrogation of macrophage-dependent injury in experimental glomerulonephritis in the rabbit. Use of an antimacrophage serum.

Authors:  S R Holdsworth; T J Neale; C B Wilson
Journal:  J Clin Invest       Date:  1981-09       Impact factor: 14.808

8.  Modulation of antibody-mediated glomerular injury in vivo by IL-1ra, soluble IL-1 receptor, and soluble TNF receptor.

Authors:  A M Karkar; F W Tam; A Steinkasserer; R Kurrle; K Langner; B J Scallon; A Meager; A J Rees
Journal:  Kidney Int       Date:  1995-12       Impact factor: 10.612

9.  The IL-23/Th17 axis contributes to renal injury in experimental glomerulonephritis.

Authors:  Hans-Joachim Paust; Jan-Eric Turner; Oliver M Steinmetz; Anett Peters; Felix Heymann; Christoph Hölscher; Gunter Wolf; Christian Kurts; Hans-Willi Mittrücker; Rolf A K Stahl; Ulf Panzer
Journal:  J Am Soc Nephrol       Date:  2009-04-01       Impact factor: 10.121

10.  Interleukin-1 receptor antagonist ameliorates experimental anti-glomerular basement membrane antibody-associated glomerulonephritis.

Authors:  W W Tang; L Feng; J L Vannice; C B Wilson
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

View more
  22 in total

1.  Effector memory T lymphocytes in renal disease.

Authors:  David L Mattson
Journal:  Am J Physiol Renal Physiol       Date:  2010-08-25

2.  Usefulness of targeting lymphocyte Kv1.3-channels in the treatment of respiratory diseases.

Authors:  Itsuro Kazama; Tsutomu Tamada; Masahiro Tachi
Journal:  Inflamm Res       Date:  2015-07-24       Impact factor: 4.575

Review 3.  Discovery of KV 1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges.

Authors:  Špela Gubič; Louise A Hendrickx; Žan Toplak; Maša Sterle; Steve Peigneur; Tihomir Tomašič; Luis A Pardo; Jan Tytgat; Anamarija Zega; Lucija P Mašič
Journal:  Med Res Rev       Date:  2021-05-01       Impact factor: 12.944

Review 4.  Physiological significance of delayed rectifier K(+) channels (Kv1.3) expressed in T lymphocytes and their pathological significance in chronic kidney disease.

Authors:  Itsuro Kazama
Journal:  J Physiol Sci       Date:  2014-08-06       Impact factor: 2.781

5.  Expression of T-cell KV1.3 potassium channel correlates with pro-inflammatory cytokines and disease activity in ulcerative colitis.

Authors:  Lars Koch Hansen; Linda Sevelsted-Møller; Maj Rabjerg; Dorte Larsen; Tine Plato Hansen; Lone Klinge; Heike Wulff; Torben Knudsen; Jens Kjeldsen; Ralf Köhler
Journal:  J Crohns Colitis       Date:  2014-05-03       Impact factor: 9.071

6.  The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression.

Authors:  Jenny Lam; Heike Wulff
Journal:  Drug Dev Res       Date:  2011-11       Impact factor: 4.360

Review 7.  Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases.

Authors:  Victor Chi; Michael W Pennington; Raymond S Norton; Eric J Tarcha; Luz M Londono; Brian Sims-Fahey; Sanjeev K Upadhyay; Jonathan T Lakey; Shawn Iadonato; Heike Wulff; Christine Beeton; K George Chandy
Journal:  Toxicon       Date:  2011-08-12       Impact factor: 3.033

Review 8.  Ion channels in innate and adaptive immunity.

Authors:  Stefan Feske; Heike Wulff; Edward Y Skolnik
Journal:  Annu Rev Immunol       Date:  2015       Impact factor: 28.527

9.  Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.

Authors:  Eric J Tarcha; Victor Chi; Ernesto J Muñoz-Elías; David Bailey; Luz M Londono; Sanjeev K Upadhyay; Kayla Norton; Amy Banks; Indra Tjong; Hai Nguyen; Xueyou Hu; Greg W Ruppert; Scott E Boley; Richard Slauter; James Sams; Brian Knapp; Dustin Kentala; Zachary Hansen; Michael W Pennington; Christine Beeton; K George Chandy; Shawn P Iadonato
Journal:  J Pharmacol Exp Ther       Date:  2012-05-25       Impact factor: 4.030

10.  Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis--xenograft model.

Authors:  Smriti Kundu-Raychaudhuri; Yi-Je Chen; Heike Wulff; Siba P Raychaudhuri
Journal:  J Autoimmun       Date:  2014-08-28       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.